ATE225400T1 - Verwendung der leserahmen der adenoviralen e4- region zur verbesserung der genexpression - Google Patents

Verwendung der leserahmen der adenoviralen e4- region zur verbesserung der genexpression

Info

Publication number
ATE225400T1
ATE225400T1 AT99401645T AT99401645T ATE225400T1 AT E225400 T1 ATE225400 T1 AT E225400T1 AT 99401645 T AT99401645 T AT 99401645T AT 99401645 T AT99401645 T AT 99401645T AT E225400 T1 ATE225400 T1 AT E225400T1
Authority
AT
Austria
Prior art keywords
expression
adenoviral
improve
gene expression
orf6
Prior art date
Application number
AT99401645T
Other languages
English (en)
Inventor
Majid Mehtali
Monika Lusky
Original Assignee
Transgene Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transgene Sa filed Critical Transgene Sa
Application granted granted Critical
Publication of ATE225400T1 publication Critical patent/ATE225400T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • AIDS & HIV (AREA)
  • Endocrinology (AREA)
AT99401645T 1998-07-07 1999-07-01 Verwendung der leserahmen der adenoviralen e4- region zur verbesserung der genexpression ATE225400T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98401722 1998-07-07
EP98402825 1998-11-13

Publications (1)

Publication Number Publication Date
ATE225400T1 true ATE225400T1 (de) 2002-10-15

Family

ID=26151663

Family Applications (2)

Application Number Title Priority Date Filing Date
AT01124236T ATE258228T1 (de) 1998-07-07 1999-07-01 Verwendung der leserahmen der adenoviralen e4- region zur verbesserung der genexpression
AT99401645T ATE225400T1 (de) 1998-07-07 1999-07-01 Verwendung der leserahmen der adenoviralen e4- region zur verbesserung der genexpression

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT01124236T ATE258228T1 (de) 1998-07-07 1999-07-01 Verwendung der leserahmen der adenoviralen e4- region zur verbesserung der genexpression

Country Status (11)

Country Link
US (1) US6475480B1 (de)
EP (2) EP0974668B1 (de)
JP (1) JP2000106875A (de)
AT (2) ATE258228T1 (de)
AU (1) AU756607B2 (de)
CA (1) CA2276791A1 (de)
DE (2) DE69903229T2 (de)
DK (2) DK1199368T3 (de)
ES (2) ES2180258T3 (de)
HK (1) HK1043390A1 (de)
PT (2) PT974668E (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6225113B1 (en) * 1998-12-04 2001-05-01 Genvec, Inc. Use of trans-activation and cis-activation to modulate the persistence of expression of a transgene in an at least E4-deficient adenovirus
WO2001092549A2 (en) * 2000-05-31 2001-12-06 Genvec, Inc. Method and composition for targeting an adenoviral vector
EP1203819A3 (de) 2000-10-06 2002-08-07 Transgene S.A. Entzündungshemmende Vektoren
US20040106194A1 (en) * 2002-08-22 2004-06-03 Bett Andrew J. Methods for propagating adenovirus and virus produced thereby
ATE500267T1 (de) 2003-07-21 2011-03-15 Transgene Sa Multifunktionelle cytokine
SG158133A1 (en) * 2004-12-31 2010-01-29 Sonne Holm Method for reversing multiple resistance in animal cells
WO2008073893A2 (en) * 2006-12-08 2008-06-19 Adv Technologies Llc Methods for producing an adenovirus type 5 gene transfer vector
US8465732B2 (en) * 2007-01-19 2013-06-18 Cornell Research Foundation, Inc. Endothelial cells expressing adenovirus E4ORF1 and methods of use thereof
BR112013003579A2 (pt) * 2010-08-16 2016-06-07 Salk Inst For Biological Studi adenovírus, células, e, métodos para tratar câncer
KR101522341B1 (ko) * 2012-10-02 2015-05-21 국립암센터 신규한 조건부-복제 가능 아데노바이러스 및 그의 제조 방법
EP3587455A1 (de) 2012-10-23 2020-01-01 Emory University Gm-csf- und il-4-konjugate, zusammensetzungen und zugehörige verfahren
SG11201507393TA (en) 2013-03-14 2015-10-29 Salk Inst For Biological Studi Oncolytic adenovirus compositions
KR102608590B1 (ko) 2014-09-24 2023-12-01 솔크 인스티튜트 포 바이올로지칼 스터디즈 종양 살상 바이러스 및 이의 사용방법
WO2017147265A1 (en) 2016-02-23 2017-08-31 Salk Institute For Biological Studies High throughput assay for measuring adenovirus replication kinetics
WO2017147269A1 (en) 2016-02-23 2017-08-31 Salk Institute For Biological Studies Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics
US11826423B2 (en) 2016-11-16 2023-11-28 Immunomic Therapeutics, Inc. Nucleic acids for treatment of allergies
EP3532082A4 (de) 2016-12-12 2020-08-26 Salk Institute for Biological Studies Auf tumoren gerichtete synthetische adenoviren und verwendungen davon
IL270024B2 (en) 2017-04-22 2025-04-01 Immunomic Therapeutics Inc LAMP structures and their use in vaccination
KR20200016224A (ko) 2017-05-02 2020-02-14 이뮤노믹 쎄라퓨틱스, 인크. 암 항원을 포함하는 lamp (리소솜 연관 막 단백질) 구축물
EP3634449A4 (de) 2017-05-08 2021-03-17 Gritstone Oncology, Inc. Alphavirus-neoantigen-vektoren
CN112292449A (zh) 2018-04-09 2021-01-29 萨克生物研究学院 具有增强的复制特性的溶瘤腺病毒组合物
EP3793595A1 (de) 2018-05-15 2021-03-24 Immunomic Therapeutics, Inc. Verbesserte lamp-konstrukte mit allergenen
MX2021014525A (es) * 2019-05-30 2022-03-17 Gritstone Bio Inc Adenovirus modificados.
JP2022551732A (ja) 2019-10-18 2022-12-13 イミュノミック セラピューティックス， インコーポレイテッド がん抗原を含む改良ｌａｍｐ構築物
CN110656090B (zh) * 2019-10-28 2023-06-30 嘉兴安宇生物科技有限公司 一种表达质粒、用于包装容量增加的二代腺病毒的细胞株及其应用
CN110714027A (zh) * 2019-10-28 2020-01-21 嘉铭(固安)生物科技有限公司 一种表达质粒、用于包装二代腺病毒的细胞株及其应用
WO2022007800A1 (zh) * 2020-07-06 2022-01-13 嘉兴安宇生物科技有限公司 一种非洲猪瘟的重组腺病毒疫苗及其构建方法
US12098384B2 (en) 2021-01-21 2024-09-24 Cellid Co., Ltd. Adenoviral vector not including replication competent adenovirus, and use thereof
EP4508071A1 (de) 2022-04-10 2025-02-19 Immunomic Therapeutics, Inc. Bicistronische lampenkonstrukte mit immunreaktionserhöhenden genen und verfahren zur verwendung davon

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5670488A (en) * 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
EP1024198A3 (de) * 1992-12-03 2002-05-29 Genzyme Corporation Pseudo-adenovirenvectors zur Gentherapie der Hämophilien
FR2726285B1 (fr) * 1994-10-28 1996-11-29 Centre Nat Rech Scient Adenovirus depourvus de particules contaminantes viables, preparation et utilisation
US5756283A (en) * 1995-06-05 1998-05-26 The Trustees Of The University Of Pennsylvania Method for improved production of recombinant adeno-associated viruses for gene therapy
US6110744A (en) * 1996-11-13 2000-08-29 Board Of Regents, The University Of Texas System Diminishing viral gene expression by promoter replacement
US5981275A (en) * 1997-04-14 1999-11-09 Genzyme Corporation Transgene expression system for increased persistence
US6100086A (en) 1997-04-14 2000-08-08 Genzyme Corporation Transgene expression systems

Also Published As

Publication number Publication date
ES2210081T3 (es) 2004-07-01
HK1043390A1 (en) 2002-09-13
DE69914382T2 (de) 2004-11-04
DE69903229D1 (de) 2002-11-07
ATE258228T1 (de) 2004-02-15
US6475480B1 (en) 2002-11-05
CA2276791A1 (en) 2000-01-07
EP1199368A3 (de) 2002-07-17
PT1199368E (pt) 2004-04-30
DK1199368T3 (da) 2004-04-13
PT974668E (pt) 2003-01-31
ES2180258T3 (es) 2003-02-01
EP0974668A1 (de) 2000-01-26
AU3800999A (en) 2000-06-08
DK0974668T3 (da) 2002-11-11
EP0974668B1 (de) 2002-10-02
EP1199368A2 (de) 2002-04-24
AU756607B2 (en) 2003-01-16
EP1199368B1 (de) 2004-01-21
JP2000106875A (ja) 2000-04-18
DE69903229T2 (de) 2003-06-26
DE69914382D1 (de) 2004-02-26

Similar Documents

Publication Publication Date Title
ATE258228T1 (de) Verwendung der leserahmen der adenoviralen e4- region zur verbesserung der genexpression
PL397823A1 (pl) Sposób identyfikacji serotypu sekwencji wirusa stowarzyszonego z adenowirusem (AAV), zestaw diagnostyczny, sposób izolacji nowych wirusów, nowy serotyp wirusa, wyizolowane wirusy, białka obejmujące fragment białka kapsydu AAV, sztuczne białka, zrekombinowany wirus, cząsteczki, sposób wytwarzania zrekombinowanych wirusów, komórki gospodarza, kompozycje, sposób dostarczania transgenu, wyizolowany AAV, rekombinowana komórka, sposób wytwarzania rekombinowanego wirusa, zastosowanie wirusa
EP0851769A4 (de) Gentherapie mit hilfe von schaf-adenoviralen vektoren
WO2001083692A3 (en) Recombinant aav vectors with aav5 capsids and aav5 vectors pseudotyped in heterologous capsids
CA2362454A1 (en) Viral vectors and viral vaccines based on recombinant porcine adenoviruses
SG142300A1 (en) Promoters for expression in modified vaccinia virus ankara
WO1998055639A3 (fr) Vecteurs adenoviraux recombinants comprenant une sequence d'epissage
CA2167578A1 (en) Chicken anemia virus mutants and vaccines and uses based on the viral proteins vp1, vp2 and vp3 or sequences of that virus coding therefor
WO2001073028A3 (en) A p-selectin glycoprotein ligand (psgl-1) binding protein and uses therefor
EP0752888A4 (de) NUKLEOTID- AMINOSÄURESEQUENZEN DER HERPEVIREN gB,gC UND gD AUS HUND UND IHRE VERWENDUNGEN
DE69929530D1 (de) Attenuierte pferdeherpesvirus
IL94053A0 (en) Methods and nucleic acid sequences for the expression of the cellulose synthase operon
MXPA02012593A (es) Particulas de tipo virus del virus de la diarrea viral bovina.
WO2006116267A3 (en) Cell-specific molecule and method for importing dna into osteoblast nuclei
EP0774002A4 (de) Dna kodierend für das schaf-adenovirus (oav287) und ihre verwendung als viralen vektor
EP1845163A3 (de) Adeno-assoziierte Virus-Serotyp-I-Nukleinsäuresequenzen und diese enthaltende Vektoren und Wirtszellen
Leigh et al. Genome sequence of PM2-like phage Cr39582, induced from a Pseudoalteromonas sp. isolated from the gut of Ciona robusta. Genome Announc 6: e00368-18
XIAO et al. STUDY OF TT VIRUS IN EXPERIMENTALLY INFECTED RHESUS MONKEY
Agrawal et al. 800. Generation of Recombinant Skin In Vitro by Adeno-Associated Virus Type 2 Vector Transduction
TANG et al. Cloning of P1 and P3 promoters of human insulin-like growth factorⅡ gene
SUN et al. Development of packageable replication-defective HBV mutants and experimental study on their anti-HBV effects by expressing antisense RNA
WU et al. Cloning and bioinformatics analysis of gene F protein binding protein 1 of hepatitis C virus
Theopold et al. 797. A Trans-Dominant Negative and Replication Defective HSV-1 Vector for In Vivo and Ex Vivo Gene Transfer
LIN et al. Construction of recombinant adenoviruses carrying human hepatocyte growth factor and investigation of its effect on human fetal hepatocytes in vitro
ZHUANG et al. Relationship between genetic diversity of surface protein of Streptococcus mutans and dental caries. Ⅱ Sequence of V-region and P-region gene of surface protein of Streptococcus mutans

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0974668

Country of ref document: EP

REN Ceased due to non-payment of the annual fee